Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults

Background. Older and sicker adults with type 2 diabetes (T2D) were underrepresented in randomized trials of glucagon-like peptide 1 receptor-agonist (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2I), and thus, health benefits are uncertain in this population. Objective. To assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dadwani, Rahul S., Wan, Wen, Skandari, M. Reza, Huang, Elbert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363885/
https://www.ncbi.nlm.nih.gov/pubmed/37492502
http://dx.doi.org/10.1177/23814683231187566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363885/
https://www.ncbi.nlm.nih.gov/pubmed/37492502
http://dx.doi.org/10.1177/23814683231187566

Ejemplares similares